The current state of biomarkers in systemic sclerosis

Research output: Contribution to journalReview articlepeer-review

Abstract

Scleroderma is a complex, multisystem autoimmune rheumatic disease with wide heterogeneity in phenotype and outcome. There are often coexisting ongoing pathologic processes including immune system activation, progressive fibrosis, and vascular disease in subsets of patients. Currently, it is challenging to identify patients at risk for developing adverse outcomes and to determine which patients are responding to current therapies. For these reasons, it is highly valuable to find easily measurable biomarkers that may represent ongoing disease activity or treatment response. This review examines the current state of biomarker development in systemic sclerosis and identifies areas in which further work should be directed.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
JournalCurrent rheumatology reports
Volume12
Issue number1
DOIs
StatePublished - Feb 1 2010

Keywords

  • Biomarkers
  • Fibrosis
  • Pulmonary hypertension
  • Scleroderma

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'The current state of biomarkers in systemic sclerosis'. Together they form a unique fingerprint.

Cite this